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Linear biocompatible glyco-
polyamidoamines as dual action 
mode virus infection inhibitors 
with potential as broad-spectrum 
microbicides for sexually 
transmitted diseases
Nicolò Mauro1,†, Paolo Ferruti1,2, Elisabetta Ranucci1, Amedea Manfredi1, Angela Berzi3, 
Mario Clerici4, Valeria Cagno5, David Lembo5, Alessandro Palmioli1,‡ & Sara Sattin1
The initial steps of viral infections are mediated by interactions between viral proteins and cellular 
receptors. Blocking the latter with high-affinity ligands may inhibit infection. DC-SIGN, a C-type lectin 
receptor expressed by immature dendritic cells and macrophages, mediates human immunodeficiency 
virus (HIV) infection by recognizing mannose clusters on the HIV-1 gp120 envelope glycoprotein. 
Mannosylated glycodendrimers act as HIV entry inhibitors thanks to their ability to block this receptor. 
Previously, an amphoteric, but prevailingly cationic polyamidoamine named AGMA1 proved effective 
as infection inhibitor for several heparan sulfate proteoglycan-dependent viruses, such as human 
papilloma virus HPV-16 and herpes simplex virus HSV-2. An amphoteric, but prevailingly anionic PAA 
named ISA23 proved inactive. It was speculated that the substitution of mannosylated units for a 
limited percentage of AGMA1 repeating units, while imparting anti-HIV activity, would preserve the 
fundamentals of its HPV-16 and HSV-2 infection inhibitory activity. In this work, four biocompatible 
linear PAAs carrying different amounts of mannosyl-triazolyl pendants, Man-ISA7, Man-ISA14, Man-
AGMA6.5 and Man-AGMA14.5, were prepared by reaction of 2-(azidoethyl)-α-D-mannopyranoside and 
differently propargyl-substituted AGMA1 and ISA23. All mannosylated PAAs inhibited HIV infection. 
Both Man-AGMA6.5 and Man-AGMA14.5 maintained the HPV-16 and HSV-2 activity of the parent 
polymer, proving broad-spectrum, dual action mode virus infection inhibitors.
Viral entry, the first stage of viral infection, is mediated by multiple interactions between viral attachment pro-
teins and specific cellular receptors1. Blocking these cell receptors with high-affinity, selective ligands is a strategy 
for devising antiviral agents, and multivalency is a powerful chemical tool to address this issue2–5. Dendritic 
Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), a C-type lectin receptor pri-
marily expressed on the surface of immature dendritic cells (DCs) and macrophages, acts as recognition molecule 
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in the modulation of the innate immune system response. DC-SIGN also plays a prominent role in the early 
infection stages of several human pathogens, including, among others, human immunodeficiency virus (HIV)6,7. 
DC-SIGN binds to glycan ligands found on both human cells and bacterial or parasitic pathogens, with a recog-
nized specificity for those containing mannose and fucose8. It specifically recognizes high-mannose clusters on 
the gp120 envelope glycoprotein of HIV-19, establishes strong multipoint interactions and promotes viral inter-
nalization and trans-infection of the T-lymphocytes facilitating HIV dissemination10. The lectin is presented at the 
surface of dendritic cells as a tetramer, with four identical carbohydrate recognition domains (CRDs) that interact 
in a Ca2+ dependent manner with their glycan targets. Each CRD contains a sugar-binding Ca2+ site and the sites 
are separated by about 4 nm11. Synthetic multivalent ligands with DC-SIGN affinity have the potential to block 
viral entry12,13. Mannosylated glycodendrimers14 glycopolymers9 and glycosylated nanoparticles15,16 have been 
developed to this target. These materials showed good activities only when a high number of mannose units was 
displayed. At lower loadings, more complex but also more active ligands (i.e. oligomannosides of variable size) 
were preferred.
Recently, it has been demonstrated that a tetravalent presentation of a pseudo-trimannoside interacts with 
DC-SIGN and blocks HIV-1 infection both in cellular and in human cervical explanted models and that glyco-
dendrimers bearing multiple copies of pseudo-mannosyl groups exert HIV and Dengue inhibitory activity17–19.
Many viruses, bacteria, and parasites express adhesins that facilitate initial cell attachment and subsequent 
infection by binding to cell surface Heparan Sulfate ProteoGlycans (HSPGs)20. Polycations may prevent virus 
adsorption by electrostatically interacting either with the negatively charged cell membrane, or with the enve-
lope of lipid-enveloped viruses. For instance, Eudragit E 100, a cationic poly(acrylic ester), was active against 
several lipid-enveloped viruses21. Cell pre-incubation with polyethylenimine reduced human papilloma virus 
(HPV) and human cytomegalovirus (HCMV) infections22. Poly-L-lysine, poly-L-arginine, poly-L-histidine and 
cationic polysaccharides were significantly active against herpes simplex virus (HSV)23. Unfortunately, many syn-
thetic polycations active against HSPG-dependent viruses are significantly cytotoxic. This is not the case of linear 
polyamidoamines (PAAs), a family of mostly water-soluble polymers obtained by Michael-type polyaddition of 
prim- or bis-sec-amines with bisacrylamides, that can be planned to be biocompatible and biodegradable24. Two 
amphoteric PAAs, named ISA2325,26 and AGMA127–29 whose chemical structures are reported in Fig. 1, proved 
exceptionally cytobiocompatible.
Their isoelectric points were 5.2 (ISA23) and 10.3 (AGMA1). At pH 7.4 they carried on average − 0.50 
and + 0.55 excess charge per unit, respectively. In infection inhibition tests, carried out in vitro on a panel of 
HSPG-dependent viruses, namely HSV, HPV, human cytomegalovirus (HCMV) and respiratory syncytial virus 
(RSV), AGMA1 was remarkably active30,31. The AGMA1 activity was attributed to its ability to interact with 
HSPGs32. However, AGMA1 did not inhibit HIV infection. In all cases, ISA23 proved completely inactive owing 
to its prevailingly anionic charge, not apt to provide significant interactions with HSPGs.
It was speculated that the substitution of mannosylated units for a limited percentage of AGMA1 repeating 
units, while imparting anti-HIV activity, would essentially preserve the fundamentals of its HPV-16 and HSV-2 
infection inhibitory activity. If verified, this hypothesis opened the way to dual-action-mode broad-spectrum 
polymeric antiviral agents. In this line, partially mannosylated ISA23 and AGMA1 were prepared as potential 
DC-SIGN antagonists, and tested as HIV-1 trans infection inhibitors. The reason for choosing two PAAs of dif-
ferent physico-chemical and antiviral properties was to discriminate between a possible anti-HIV activity due 
solely to the mannosyl pendants, and an anti-HIV activity benefitting from a synergistic effect by the polymer 
chain. Such an effect was hardly predictable for mannosylated ISA23, but could not be excluded for mannosylated 
AGMA1, since the establishment of HIV interactions with cell membrane HSPGs is an early step of the infection.
Results and Discussion
Synthesis. ISA23 and AGMA1 are normally prepared by stepwise polyaddition of 2,2-bis(acrylamido)acetic 
acid with, respectively, 2-methylpiperazine and 4-amminobutylguanidine (agmatine). In this work, mannosylated 
ISA23 and AGMA1 were prepared in two steps (details provided in the Supplementary Information). In the 
first step, two modified ISA23 (P-ISA) and two modified AGMA1 (P-AGMA) carrying propargyl pendants were 
prepared by substituting 10- or 20% (on a molar basis) propargylamine for 2-methylpiperazine or agmatine in 
the polymerization recipes (Fig. 2). The crude products were purified by ultrafiltration through a membrane with 
nominal cut-off 3000. In the purified products, the actual percentages on a molar basis of propargylamine-bearing 
Figure 1. Chemical structures of ISA23 and AGMA1. 
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repeating units were, as assessed by 1H NMR, 7.0% and 14.0% (ISA23); 6.5% and 14.5% (AGMA1). Accordingly, 
the final products were named P-ISA7, P-ISA14, P-AGMA6.5 and P-AGMA14.5. There is no reason to believe that the 
propargyl units were orderly inserted in the polymer chains, since stepwise polyaddition reactions of monomer 
mixtures with similar reactivity normally lead to random copolymers. In the second step, a copper acetate-cata-
lyzed alkyne-azide cycloaddition (“click” reaction) was performed between the propargylamine-modified PAAs 
and 2-(azidoethyl)-α -D-mannopyranoside, leading to the corresponding mannosylated ISA23 (Man-ISA7, Man-
ISA14) and AGMA1 (Man-AGMA6.5 and Man-AGMA14.5).
The copper ions were removed from the final products by carefully acidifying to pH 3.5 with hydrochloric 
acid and ultrafiltering through a membrane with nominal cut-off 3000. The residual copper content, as deter-
mined by atomic absorption was in all cases < 0.01% on a w/w basis. The retained fractions were finally retrieved 
by lyophilization. The representative NMR spectra of P-ISA7, Man-ISA7, P-AGMA6.5 and Man-AGMA6.5 are 
reported in Figs S1–S4. The quantitative assessment of the percentage of substitution of propargylamine units was 
performed from the relative intensities of the integrals of the CH2 α to the triple bond (4.18 ppm) and CHCOOH 
(5.58 or 5.63 ppm for P-ISA and P-AGMA, respectively) peaks. The crosspeak signal of this CH2 in the HSQC 
spectra disappeared in the mannosylated products (compare Figs S1–S4). This was assumed as an indication that 
the reaction approached completion.
Biossays. HIV infection inhibitory activity. The ability of Man-ISA and Man-AGMA samples to inhibit 
HIV-1 trans infection of CD4+ T lymphocytes was evaluated exploiting the B-THP-1/DC-SIGN cells as a 
model of dendritic cells (DCs). This model is well-established and has been repeatedly shown to depend on 
DC-SIGN10,33,34 by using BTHP-1 cells not expressing DC-SIGN as a negative control. Trans infection of CD4+ T 
lymphocytes was monitored by enzyme-linked immunosorbent assay (ELISA) for the HIV-1 protein p2417. The 
results are reported in Fig. 3, where concentrations are referred to the mannose units and shown as percent inhi-
bition relative to the culture medium (negative) control, which is assigned 100% infection value. The previously 
described PM19, a highly potent hexavalent glycomimetic, is used as a positive control (compound 13.4 in ref. 17). 
Of note, the efficacy of monovalent mannose is too low to be measured in the millimolar concentration range 
used in these tests. Results show for all samples a mannosyl-concentration-dependent HIV infection inhibiting 
activity. The same tests confirmed the inefficacy in this respect of plain ISA23 and AGMA1.
It may be noticed that the mannosylated PAAs reported here were significantly active against HIV notwith-
standing their molecular architecture lacked a well-defined steric arrangement of the saccharide groups, since 
Figure 2. Synthesis of (a) Man-ISA and (b) Man-AGMA polymers. Two batches of each polymer were 
prepared with different content of propargylamine bearing repeating units: P-ISA7 and P-ISA14 (7.0 and 14.0%); 
P-AGMA6.5 and P-AGMA14.5 (6.5 and 14.5%). The corresponding mannosylated polymers had the same 
mannosyl unit content.
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the propargylamine units (hence the mannosyl pendants in the final product) were expected to be randomly 
distributed along the polymer chain, as it is the rule in stepwise polyaddition polymers. In mannosylated PAAs, 
the mannosyl groups were attached as pendants to linear, mobile polymer chains that in solution could assume 
multiple conformations.
The molecular weights and, per macromolecule, the average number of repeating units and the average num-
ber of mannosyl pendants are reported in Table 1.
With the exception of Man-ISA14, the molecular weights were not very high and, notably, the number of man-
nosyl pendants per macromolecule was modest. None of these factors played a role in determining the antiviral 
activity, which solely depended on the mannosyl group concentration in the culture medium. As evident from 
Fig. 3, in fact, the amount of mannosylated PAA needed to reach a given level of anti-HIV activity was in all cases 
inversely proportional to its mannosylation degree. In other words, the specific activity of the mannosyl pendants 
attached to both ISA23 and AGMA1 was independent of their frequency along the PAA chain as well as of the 
PAA’s nature, molecular weight and net average charge in the culturing medium. It had been previously found 
that amphoteric PAAs, different from non-amphoteric ones, give molecular aggregates in aqueous media owing 
to ionic interactions35.
In the present case, the ability of forming clusters, combined with the intrinsic conformational mobility of the 
polymer chains, probably allowed several mannosyl groups attached to either the same or different macromole-
cules to cooperate in establishing strong interactions with the lectin receptors.
No synergistic effect on the anti-HIV activity of the AGMA1 carrier was demonstrated. Finally, it may be 
noticed that the HIV infection inhibitory activity of Man-ISA14 and Man-AGMA14.5 was comparable to that of 
G3Man32, a previously reported Bolton mannosylated dendrimer with valence 3236. Although higher activity 
dendrimers have been reported19, they all carry monovalent ligands intrinsically more active than mannose. The 
anti-HIV activity of Man-AGMA and Man-ISA samples was not due to cytotoxic effect on the host DCs since, 
as shown in Fig. S5, no appreciable cell toxicity was observed in the concentration range adopted in the infection 
inhibitory activity tests. This corresponds to the cytobiocompatibility of plain ISA23 and AGMA1. The introduc-
tion of mannosyl-triazolyl pendants was apparently inconsequential in this respect.
HPV and HSV infection inhibitory activity. As mentioned, AGMA1 had previously proven endowed with 
intrinsic antiviral activity towards several HSPG dependent viruses, including HPV and HSV, and represents 
a good positive control of inhibition. The experiments were performed on the oncogenic HPV-16 and HSV-2, 
Figure 3. HIV trans infection levels. HIV-1 productive infection was measured as amount of p24 protein 
in the co-culture supernatants. Experiments were performed on CD4+ T lymphocytes isolated from 3 
different healthy donors. Data represent the percent HIV-1 infection following polymer treatment in 
comparison with the untreated control (MED, set as 100% of HIV infection). For Man-AGMA and Man-ISA 
samples, concentrations refer to the mannosylated units. In case of plain ISA23 and AGMA1, the same w/v 
concentrations of Man-ISA7 and Man-AGMA6.5 were used, respectively. Values represent the mean ± SD. 
Statistical analysis was performed using one-way ANOVA followed by the Bonferroni’s post hoc test. *P < 0.05, 
**P < 0.01, ***P < 0.001.
Sample Mn PD
Average N° repeating units 
per macromolecule
Average N° mannosyl 
residues per macromolecule
Man-ISA7 8700 1.09 28 1.96
Man-ISA14 21900 1.44 67 9.38
Man-AGMA6.5 7500 1.21 22 1.43
Man-AGMA14.5 8100 1.21 23 3.33
Table 1.  Molecular weight, average number of repeating units and number of mannosyl pendants of 
mannosylated PAAs.
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both sexually transmitted and often associated to HIV infections37. As shown in Fig. 4, neither ISA23 nor its 
mannosylated derivatives exerted any HPV-16 and HSV-2 infection inhibitory activity. On the opposite, both 
Man-AGMA6.5 and Man-AGMA14.5 were significantly active against both viruses. Interestingly, at low concen-
tration, Man-AGMA14.5 was less active, likely because the mannosylated units had replaced an equal number 
of guanidine-bearing units that, according to previous studies31, are responsible for the AGMA1 anti-HPV and 
anti-HSV activity. Of note, also in these experiments none of the compounds proved cytotoxic at the tested doses 
and at the same time-points used for antiviral assays (Figs S6 and S7), further confirming that antiviral activity 
was not a consequence of cytotoxicity.
Experimental Section
Chemistry section. (Detailed information is available in Supplementary Information).
Biological section. HIV assay. In vitro trans-infection assay of CD4+ T lymphocytes. The assay was per-
formed as previously described38,39. All experimental protocols were approved by the Institutional Review Board 
of Vimercate Hospital (Italy). CD4+ T lymphocytes were purified from Peripheral Blood Mononuclear Cells 
(PBMCs) isolated from buffy coats obtained from healthy volunteers after written informed consent and all meth-
ods were carried out in accordance with the approved guidelines. Briefly, B-THP1/DC-SIGN and B-THP1 cells 
(NIBSC, Potter Bar, UK) were pre-incubated for 30 min with the polymers and then pulsed with 40 TCID50 HIV-1 
BaL (NIBSC, Potter Bar, UK), without removing the inhibitors for 3 h. After washing, the cells were cultured with 
the pre-activated CD4+ T lymphocytes for 3 days. HIV p24 concentration in the co-culture supernatants was 
assessed by ELISA (Express Bio, Thurmont, MD, USA).
BTHP1-DC-SIGN Cell viability assay. BTHP1-DC-SIGN cells were incubated with the polymer samples for 
different time points (3 h and 30 min, 24 h, and 72 h) and then labelled with 7-aminoactinomycin D (7-AAD) 
(Beckman Coulter, Milan, Italy). Samples were acquired by using a Gallios™ Flow Cytometer and data were ana-
lysed with Kaluza® Flow Analysis Software (both from Beckman Coulter). HeLa and Vero cells were seeded at in 
96-well plates; the next day, they were treated with serially diluted compounds. After 24 or 72 h of incubation, cell 
viability was determined using the CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA), according 
to the manufacturer’s instructions. Absorbances were measured using a Microplate Reader (Model 680, BIORAD) 
at 490 nm.
HPV assay. Cell culture. The human cervical carcinoma cell lines HeLa were grown as monolay-
ers in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco-BRL, Gaithersburg, MD) supplemented with 
heat-inactivated 10% fetal calf serum (FCS; Gibco- BRL). The 293TT cell line, derived from human embryonic 
kidney cells transformed with the simian virus 40 (SV40) large T antigen, was cultured in the medium described 
above supplemented with nonessential amino acids. 293TT cells allow high levels of protein to be expressed from 
vectors containing the SV40 origin due to overreplication of the expression plasmid40. African green monkey 
fibroblastoid kidney cells (Vero, ATCC CCL-81) were grown as monolayers in Eagle’s minimal essential medium 
Figure 4. (a) HPV-16 and (b) HSV-2 infection inhibitory activity. Data represent the percent infection 
following polymer treatment in comparison with the untreated control. For Man-AGMA and Man-ISA 
samples, concentrations refer to the mannosylated units. In case of plain ISA23 and AGMA1, the same w/v 
concentrations of Man-ISA7 and Man-AGMA6.5 were used, respectively. Values represent the mean ± SD. 
Statistical analysis was performed using two-way ANOVA followed by the Bonferroni’s post hoc test. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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(MEM) (Gibco/BRL, Gaithersburg, MD) supplemented with 10% heat inactivated fetal calf serum (FCS) and 1% 
antibiotic-antimycotic solution (Zell Shield, Minerva Biolabs GmbH, Berlin, Germany).
HPV PsV production. Plasmids and 293TT cells used for pseudovirus (PsV) production were kindly provided 
by John Schiller (National Cancer Institute, Bethesda, MD) or bought at Addgene (Cambridge, MA). Detailed 
protocols and plasmid maps for this study are reported at http://home.ccr.cancer.gov/lco/pseudovirusproduction.
htm. HPV-16 PsVs were produced according to previously described methods41. Briefly, 293TT cells were trans-
fected with plasmids expressing the papillomavirus major and minor capsid proteins (L1 and L2, respectively), 
together with a reporter plasmid expressing the green fluorescent protein (GFP), named pfwB. Capsids were 
allowed to mature overnight in cell lysate; the clarified supernatant was then loaded on top of a density gradient 
of 27 to 33 to 39% Optiprep (Sigma-Aldrich, St. Louis, MO) at room temperature for 3 h. The material was cen-
trifuged at 28000 rpm for 18 h at room temperature in an SW41.1 rotor (Beckman Coulter, Inc., Fullerton, CA) 
and then collected by bottom puncture of the tubes. Fractions were inspected for purity in 10% sodium dodecyl 
sulfate (SDS)–Tris–glycine gels, titrated on 293TT cells to test for infectivity by SEAP or GFP detection, and then 
pooled and frozen at − 80 °C until needed. The L1 protein content of PsV stocks was determined by comparison 
with bovine serum albumin standards in Coomassie-stained SDS-polyacrylamide gels32.
HPV GFP-based assays. HeLa cells were seeded in 96-well plates in 100 ml of DMEM supplemented with 10% 
FBS. The next day, serial dilutions of compounds were added to preplated cells together with dilutions of PsV 
stock. After 72 h of incubation at 37 °C fluorescent cells were counted on an inverted Zeiss LSM510 fluorescence 
microscope.
HSV assay. Viruses. A clinical isolate of HSV-2 was kindly provided by Professor M. Pistello, University of 
Pisa, Italy. HSV-2 was propagated and titrated by plaque assay on Vero cells.
HSV-2 inhibition assay. The effect of compounds on HSV-2 infection was evaluated by plaque reduction assay. 
Vero cells were pre-plated 24 h in advance in 24-well plates at a density of 10 × 104 cells. Serial dilutions of com-
pounds and HSV-2 (MOI 0.0005 pfu/cell) were added to cells for 2 h. The virus inoculum was then removed and 
the cells washed and overlaid with a medium containing 1.2% methylcellulose (Sigma-Aldrich, Milano, Italy). 
After further incubation at 37 °C for 24 h cells were fixed and stained with 0.1% crystal violet in 20% ethanol and 
viral plaques counted. The percent of infection was calculated in comparison with the untreated control.
Statistical Analysis. For infection studies, comparisons between groups were performed using one-way 
(HIV) or two-way (HPV and HSV) ANOVA followed by a Bonferroni’s Multiple Comparison Test. A P value 
less than 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). Statistical analysis was 
performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).
Conclusions
In this work, two biocompatible PAAs named ISA23 and AGMA1 functionalised with moderate amounts of 
mannosyl-triazolyl pendants, Man-ISA7, Man-ISA14, Man-AGMA6.5 and Man-AGMA14.5, were successfully pre-
pared by click reaction between 2-(azidoethyl)-α -D-mannopyranoside and partially propargyl-substituted PAA 
precursors, in turn prepared by substituting 10 or 20% (on a molar basis) propargylamine for 2-methylpiperazine 
(ISA23) or agmatine (AGMA1) in the reaction recipes. All Man-ISA and Man-AGMA samples proved effec-
tive HIV infection inhibitors notwithstanding their molecular architecture lacked a preliminarily defined spatial 
arrangement of the saccharide groups. Their inhibitory activity was independent of the nature of the PAA carrier, 
but solely governed be the concentration of mannosyl residues in the culture medium, higher substituted samples 
reaching the same efficacy at lower polymer concentrations. The antiviral activity could be probably ascribed to 
the fact that in solution the PAA carriers, having mobile conformations, may form clusters driving several man-
nosyl residues to establish multiple interactions with the lectin receptors.
AGMA1 had previously proved inactive as HIV infection inhibitor, but very active against several 
HSPG-dependent viruses. Man-AGMA6.5 and Man-AGMA14.5 maintained this activity, as tested against the sex-
ually transmitted HPV-16 and HSV-2 viruses. Thus, mannosylation imparted anti-HIV activity to both ISA23 
and AGMA1, and preserved the latter’s HPV and HSV inhibitory activity. These results point the final conclu-
sion that Man-AGMA derivatives warrant potential as dual-action-mode, broad-spectrum inhibitors of sexually 
transmitted viral infections.
As a future development, AGMA1 or ISA23 derivatives carrying different glycomimetic substituents intrinsi-
cally endowed with significant activity as DC-SIGN antagonists can be considered.
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